news.liverpool.ac.uk
A study recently published in PNAS explores the role of the protein Pentraxin 3 (PTX3) in diabetic retinopathy, a major cause of blindness among people with diabetes. The research highlights PTX3 as a molecular driver of inflammation in the diabetic retina, offering insights that could inform the development of new treatments to prevent vision loss in diabetic patients.
The study, conducted by researchers from Queen’s University Belfast, Humanitas University Milan, and the University of Liverpool, found that diabetic mice lacking PTX3 were protected from vision impairment. In these models, the absence of PTX3 led to reduced retinal inflammation and vascular degeneration, two key factors associated with diabetic retinopathy. The research utilized a combination of in vitro and in vivo models and demonstrated that PTX3 influences several retinal cell types, including Muller cells, microglia, and endothelial cells, all of which play roles in disease progression.
The discovery of PTX3 as a new molecular target in diabetic retinopathy shifts the focus toward potential treatments aimed at preventing its accumulation in the retina. According to Professor Reinhold J. Medina, the study’s corresponding author, the findings challenge the initial hypothesis that PTX3 might have a protective role in the diabetic retina. Instead, the research showed that PTX3 promotes retinal damage. This opens the door to further investigations into therapies that could slow or stop the progression of diabetic retinopathy by targeting PTX3.
Diabetic retinopathy is a serious complication of diabetes that can lead to irreversible vision loss. While current treatments provide some protection, many patients still face significant risk. The new understanding of PTX3’s role offers a potential pathway for developing treatments that could prevent vision impairment in diabetic patients. Dr. Lucy Chambers of Diabetes UK emphasized that the study’s findings may bring researchers closer to creating therapies that help more people with diabetes avoid the harmful effects of retinopathy. Ongoing research, including clinical trials, will be essential to determine whether blocking PTX3 can effectively prevent diabetic-related vision loss.